Monitor Phase 3 MAPKeeper 301 enrollment updates and any interim data releases, as the 17.3-month OS from Phase 2a sets a high bar. The cash runway into 2029 removes near-term financing risk, but the stock will move on trial milestones, not quarterly financials.
Price Chart
Executive Summary
Immuneering reported Q2 2026 net loss of $17.3M ($0.27/share), wider than the $14.4M loss in Q2 2025, driven by increased R&D spending on the Phase 3 MAPKeeper 301 trial. Cash burn accelerated to $34.3M in H1 2026 vs $30.2M in H1 2025, though the company maintains $182.7M in cash with runway into 2029. The key catalyst is the ongoing Phase 3 enrollment and the 17.3-month median overall survival data from the Phase 2a presented at ASCO, positioning atebimetinib as a potentially best-in-class first-line pancreatic cancer therapy.
Key Financial Metrics
Key Facts
- Net loss of $17.3M ($0.27/share) for Q2 2026, vs $14.4M ($0.40/share) in Q2 2025
- R&D expenses rose to $14.0M from $10.5M YoY, driven by atebimetinib Phase 3 trial costs
- Cash, cash equivalents and marketable securities of $182.7M as of June 30, 2026, down from $217.0M at year-end 2025
- Phase 3 MAPKeeper 301 trial dosing patients; over 30 study locations posted
- Phase 2a data at ASCO showed 17.3-month median overall survival in first-line pancreatic cancer
- Appointed Andrew Gengos as CFO, previously CFO at Terns Pharmaceuticals (acquired by Merck for $6.7B)
Financial Impact
Net loss widened $2.9M YoY; cash burn $34.3M in H1 2026 vs $30.2M in H1 2025; cash runway into 2029
Risk Factors
- Phase 3 trial may fail to replicate Phase 2a survival benefit
- Cash burn accelerating with no near-term revenue; dilution risk if trial costs exceed runway
- Competing therapies (e.g., NALIRIFOX, modified FOLFIRINOX) may erode atebimetinib's perceived advantage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3339218 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Press Release | — | awaiting T+1 | — | — |
Oct 2, 2026 24d ago | Press Release | $4.07 $4.04 | ▼ −0.74% | ▼ −1.41% | $3.73 (−8.35%) |
Sep 28, 2026 28d ago | Press Release | $4.16 $4.13 | ▼ −0.72% | ▼ −0.54% | $3.73 (−10.34%) |
Aug 26, 2026 8w ago | Press Release | $5.21 $4.99 | ▼ −4.22% | ▼ −4.00% | $3.73 (−28.41%) |
Aug 5, 2026 11w ago | 8-K | $4.39 $4.46 | ▲ +1.59% | ▲ +1.75% | $3.73 (−15.03%) |
Aug 5, 2026 11w ago | Press Release | $4.39 $4.46 | ▲ +1.59% | ▲ +1.75% | $3.73 (−15.03%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.12 $4.19 | ▲ +1.70% | ▲ +1.16% | $3.73 (−9.47%) |
Jun 1, 2026 20w ago | 8-K | $4.28 $4.55 | ▲ +6.31% | ▲ +7.00% | $3.73 (−12.85%) |
May 15, 2026 23w ago | Press Release | $5.16 $4.87 | ▼ −5.62% | ▼ −5.56% | $3.73 (−27.71%) |
Apr 21, 2026 26w ago | Press Release | $5.89 $6.13 | ▲ +4.07% | ▲ +4.47% | $3.73 (−36.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers